Navigating the "Prohibitive Risk" Frontier: A Contemporary Review of Mechanical Circulatory Support in Complex High-Risk Indicated Patient (CHIP) Interventions.

1 day ago
1 min read

Original Research | 2025 | Volume 1 | Issue 1 | Page 60-69

Dr. Jambia Khatoon, Assistant Professor, Cardiology, IPGMER, Kolkata

Abstract

The definition of "revascularization candidates" has undergone a radical expansion, moving into the CHIP (Complex High-Risk Indicated Patient) domain. This population is defined by a "Triple Threat" of complex coronary anatomy (CTO, multivessel disease, severe calcification), severely depressed left ventricular function (LVEF < 35%), and prohibitive surgical risk scores. This review evaluates the 2024–2026 clinical landscape, where the synergy between Mechanical Circulatory Support (MCS) and advanced interventional techniques has transformed once-fatal procedures into safe, reproducible successes.

We examine the methodological "Shift to Hemodynamic Neutrality," focusing on the clinical utility of the Impella (2.5, CP, and 5.5) micro-axial pumps and the evolving role of Extracorporeal Membrane Oxygenation (ECMO) in the "Crash-on-Table" scenario. A primary focus is placed on the concept of "Active Unloading"—the ability of MCS to reduce myocardial oxygen demand while simultaneously increasing systemic mean arterial pressure. This "physiological safety net" allows the operator to perform complete revascularization of complex lesions, including those requiring prolonged rotational atherectomy or intravascular lithotripsy (IVL). By synthesizing data from the PROTECT III and RESTORE registries, this paper discusses the impact of MCS on reducing Acute Kidney Injury (AKI) through the maintenance of renal perfusion and the mitigation of contrast-induced insult. As we look toward 2030, this review concludes that the "Prohibitive Risk" frontier is no longer defined by the patient’s frailty, but by the availability and precise application of hemodynamic support technology.